Actively Recruiting
Reduction of Polypharmacy in Elderly People With Multiple Diseases
Led by Martin-Luther-Universität Halle-Wittenberg · Updated on 2025-01-09
1146
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
Sponsors
M
Martin-Luther-Universität Halle-Wittenberg
Lead Sponsor
U
University of Leipzig
Collaborating Sponsor
AI-Summary
What this Trial Is About
Elderly GP patients are often treated with five or more medications and therefore prone to adverse drug reactions (ADR). Potentially inappropriate prescriptions (PIPs) lead to increased adverse events like falls, hospitalizations and mortality. The primary aim of this study to reduce the frequency of ADRs in multimorbid patients aged 70 years and older by reducing polypharmacy.
CONDITIONS
Official Title
Reduction of Polypharmacy in Elderly People With Multiple Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Taking five or more long-term medications (over 6 months) (polypharmacy)
- Having three or more chronic diseases (multimorbidity)
- At least one family doctor consultation within the last 6 months
You will not qualify if you...
- Critically reduced life expectancy
- Unable to visit the family practice independently
- Unable to participate in the informed consent process
- Living in a nursing home
- Diagnosed with dementia or mental/behavioral disorders (ICD-10 F00-F99)
- Currently participating in another medical study focused on polypharmacy or multimorbidity
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
HAP ANZ
Halle, Saxony-Anhalt, Germany, 06110
Actively Recruiting
Research Team
A
Alexander Bauer, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here